## User

This is the beginning of a team meeting to discuss your research project. This is a meeting with the team lead, Principal Investigator, and the following team members: Validation and Benchmarking Specialist, Computational Biologist, Scientific Critic.

Here are summaries of the previous meetings:

[begin summary 1]

### Agenda Response

**1. What are the key strengths of this protocol for generating dorsal forebrain organoids?**

**Answer:** The protocol's strengths include the use of dual SMAD inhibition for effective neural induction and the incorporation of a spinning bioreactor for uniform organoid expansion.

**Justification:** These elements are consistently highlighted across all meetings as critical for promoting neural lineage specification and ensuring even tissue growth. The dual SMAD inhibition aligns with best practices for neural induction, while the spinning bioreactor supports uniform expansion, both of which are essential for reproducibility and fidelity to human cortical development.

**Components from Summaries:** This answer draws from all three summaries, where dual SMAD inhibition and the spinning bioreactor are repeatedly mentioned as strengths. These components are foundational to the protocol's success and are well-supported by current research.

**2. What are the potential weaknesses or gaps in the protocol?**

**Answer:** The primary weaknesses include reliance on Matrigel, which introduces variability, and the use of cyclopamine alone for dorsal patterning, which may be insufficient.

**Justification:** Matrigel variability is a recurring concern across all meetings, impacting reproducibility. Additionally, relying solely on cyclopamine for dorsal patterning may not adequately reinforce dorsal identity, as noted in the third summary. Addressing these gaps is crucial for consistent outcomes.

**Components from Summaries:** This answer incorporates concerns from all summaries about Matrigel variability and the need for additional signaling modulators beyond cyclopamine, as highlighted in the third summary.

**3. What aspects of the protocol require rigorous validation?**

**Answer:** Rigorous validation is needed for cell type identity, spatial organization, developmental timing, and functional neuronal activity.

**Justification:** Ensuring that the organoids accurately model human cortical development requires comprehensive validation. This includes confirming the presence and organization of expected cell types, matching developmental timelines, and assessing functional maturation through electrophysiological assays.

**Components from Summaries:** This answer synthesizes validation needs from all summaries, emphasizing scRNA-seq, immunohistochemistry, and functional assays like MEA recordings, as discussed in the third summary.

**4. Are there any obvious risks of off-target differentiation based on the protocol design?**

**Answer:** Yes, there is a risk of ventralization and non-cortical differentiation due to incomplete SHH inhibition and variability in media conditions.

**Justification:** The potential for off-target differentiation is a concern if patterning cues are inadequate or inconsistent. This risk is highlighted in all summaries, with particular emphasis on the need for additional modulators and computational feedback to maintain dorsal specificity.

**Components from Summaries:** This answer integrates concerns from all summaries about off-target differentiation, particularly the need for precise signaling control and computational integration to mitigate these risks.

### Next Steps

1. **Matrix Exploration:** Transition from Matrigel to defined synthetic matrices like PEG or hyaluronic acid-based hydrogels to reduce variability.
   
2. **Signaling Modulator Integration:** Incorporate additional signaling pathways, such as WNT and BMP, during the patterning phase to reinforce dorsal identity.

3. **Validation Protocol Development:** Establish a timeline for regular scRNA-seq, electrophysiology, and imaging assays to ensure developmental fidelity.

4. **Computational Model Integration:** Develop predictive models to simulate protocol conditions and refine parameters dynamically based on experimental data.

5. **Functional Assay Trials:** Implement MEA recordings as a standard part of the maturation phase to assess neuronal functionality and network formation.

These steps, drawn from the collective insights of all summaries, will enhance the development of a robust and reproducible protocol for dorsal forebrain organoids, ensuring they serve as reliable models for further research.

[end summary 1]

[begin summary 2]

### Comprehensive Set of Quality Control Assays for Dorsal Forebrain Organoid Differentiation

To develop dorsal forebrain organoids that accurately model human cortical development, we must implement a robust quality control (QC) strategy. This strategy should integrate molecular, morphological, and functional assays across key developmental timepoints to ensure reproducibility and biological accuracy. Below is a consolidated plan based on previous discussions:

### 1. Early Timepoints (Day 10-25)

**QC Assays:**
- **qPCR and Immunocytochemistry (ICC):** Assess neural induction markers (PAX6, SOX1, SOX2, NES).
- **Live Imaging:** Monitor spatial organization and morphological changes.

**Expected Outcomes:**
- **Success:** >80% expression of neural induction markers, with clear spatial co-localization and morphological transitions indicative of neural lineage commitment.
- **Failure Indicators:** <70% marker expression or lack of spatial organization.

**Justification:** This approach combines the emphasis on high expression thresholds from the Developmental Biologist (Summary 3) with the spatial and morphological assessments suggested by the Scientific Critic (Summary 2). It ensures early-stage verification of neural lineage commitment.

### 2. Mid-Differentiation (Day 45-90)

**QC Assays:**
- **scRNA-seq and Spatial Transcriptomics:** Evaluate dorsal identity (FOXG1, EMX1, EMX2, LHX2) and radial glia markers (PAX6, SOX2, HES1, VIM, GFAP).
- **Quantitative Imaging:** Assess spatial organization and radial glia development.
- **Computational Modeling:** Predict differentiation paths and adjust protocols dynamically.

**Expected Outcomes:**
- **Success:** >50% expression of dorsal identity and radial glia markers, with proper spatial organization.
- **Failure Indicators:** Inadequate marker expression or disorganized spatial patterns.

**Justification:** This combines the detailed molecular assessments from the Validation and Benchmarking Specialist (Summary 2) with the predictive modeling approach from the Scientific Critic (Summary 3), ensuring accurate mid-stage validation.

### 3. Late Timepoints (Day 120+)

**QC Assays:**
- **MEA and Calcium Imaging:** Evaluate functional maturation of cortical neurons.
- **Expression Analysis:** Assess cortical neuron markers (TBR1, BCL11B, CTIP2, FEZF2, SATB2, CUX1, CUX2, BRN2).

**Expected Outcomes:**
- **Success:** Functional network formation and layer-specific differentiation, with >40-50% expression of mature neuron markers.
- **Failure Indicators:** Lack of synaptic functionality or inadequate marker expression.

**Justification:** This integrates the functional assays recommended by the Scientific Critic (Summary 2) with the expression analysis approach from the Developmental Biologist (Summary 3), ensuring comprehensive late-stage validation.

### 4. Quantitative Thresholds

**Thresholds:**
- **Early Markers:** >80% expression.
- **Mid Markers:** >50% expression.
- **Late Markers:** Functional synapse formation and >40-50% expression of mature neuron markers.

**Justification:** These thresholds reflect the rigorous standards necessary for confirming developmental fidelity, as emphasized by the Validation and Benchmarking Specialist (Summary 1) and the Developmental Biologist (Summary 3). Flexibility is incorporated to accommodate biological variability and data-driven insights.

### Next Steps

1. **Protocol Development:** Finalize detailed protocols for each assay, ensuring consistency and reproducibility.
2. **Pilot Testing:** Conduct pilot studies to validate initial screening methods and refine quantitative thresholds.
3. **Data Integration:** Establish systems for integrating molecular, morphological, and functional data.
4. **Matrix Transition:** Initiate studies to transition to synthetic matrices, as recommended in Summary 2.
5. **Training and Resources:** Ensure team members are equipped and trained for new methodologies.

This comprehensive QC strategy will ensure that our dorsal forebrain organoid protocols are robust, reproducible, and aligned with human brain development, facilitating their use in disease modeling and drug screening.

[end summary 2]

Here is the agenda for the meeting:

You are working on a research project to develop
dorsal forebrain organoids that faithfully recapitulate human cortical
development. The goal is to create reproducible, biologically accurate
organoid protocols that can be used for disease modeling, drug screening,
and understanding human brain development.

Now we need to establish how the organoid protocol outcomes will be compared
to human fetal brain developmental benchmarks. Please define specific comparisons
using established reference datasets.

Available reference datasets:
- BrainSpan (human brain transcriptome across development)
- Nowakowski 2017 (fetal cortex scRNA-seq, GW5.85-GW37)
- Polioudakis 2019 (fetal cortex scRNA-seq, GW17-GW18)
- Bhaduri 2020 (fetal cortex scRNA-seq, GW6-GW22)
- Trevino 2021 (fetal cortex scRNA-seq, GW14-GW25)

Consider:
- Transcriptomic correlation analyses
- Cell type proportion comparisons
- Developmental trajectory alignment
- Pathway activity scoring


Here are the agenda questions that must be answered:

1. Which reference datasets should be used for benchmarking organoids at each developmental stage?

2. What transcriptomic metrics should be used to assess alignment with fetal references?

3. What cell type proportions are expected at each timepoint based on fetal data?

4. How should pathway activity be scored and compared to developmental references?

Principal Investigator will convene the meeting. Then, each team member will provide their thoughts on the discussion one-by-one in the order above. After all team members have given their input, Principal Investigator will synthesize the points raised by each team member, make decisions regarding the agenda based on team member input, and ask follow-up questions to gather more information and feedback about how to better address the agenda. This will continue for 2 rounds. Once the discussion is complete, Principal Investigator will summarize the meeting in detail for future discussions, provide a specific recommendation regarding the agenda, and answer the agenda questions (if any) based on the discussion while strictly adhering to the agenda rules (if any).

## User

Principal Investigator, please provide your initial thoughts on the agenda as well as any questions you have to guide the discussion among the team members.

## Principal Investigator

As we convene to discuss the agenda, our primary focus is to ensure that our dorsal forebrain organoid protocols are not only reproducible but also biologically accurate models of human cortical development. Establishing developmental benchmarks is critical, and I'm eager to hear each team's perspective on how best to leverage the available reference datasets.

To guide our discussion, here are some initial thoughts and questions:

1. **Reference Datasets Selection:** We must carefully choose the most appropriate datasets for each stage of organoid development. Given the range of gestational weeks covered by each dataset, how do we best align these with our organoid maturation stages?

2. **Transcriptomic Metrics:** It's essential to determine which metrics will most effectively demonstrate alignment with fetal brain references. Are there specific transcriptomic patterns or gene sets we should prioritize?

3. **Cell Type Proportions:** Understanding the expected cell type proportions at each developmental stage will be crucial. How do we ensure our organoid models reflect the dynamic changes seen in fetal development?

4. **Pathway Activity Scoring:** Accurately scoring and comparing pathway activities will help validate our organoid models. What methodologies should we employ to ensure robust comparisons?

As we proceed, I encourage each team member to draw on their expertise to address these questions. The goal is to develop a comprehensive strategy for benchmarking our organoid protocols against human fetal brain developmental benchmarks. Let's start with your thoughts and insights.

## User

Validation and Benchmarking Specialist, please provide your thoughts on the discussion (round 1 of 2). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Validation and Benchmarking Specialist

Thank you for the introduction, Principal Investigator. I appreciate the opportunity to share my thoughts on this critical aspect of our project. Here's how I see our path forward regarding benchmarking our organoid protocols:

1. **Reference Datasets Selection:** For benchmarking organoids across their developmental timeline, we should strategically choose datasets that align with early, mid, and late developmental stages of the human cortex. For early stages (Day 10-25), the **Nowakowski 2017** and **Bhaduri 2020** datasets are ideal as they cover earlier gestational weeks (GW5.85-GW22). For mid-stages (Day 45-90), the **Trevino 2021** dataset is suitable given its focus on GW14-GW25. Finally, for late-stage benchmarking (Day 120+), the **Polioudakis 2019** dataset, which focuses on GW17-GW18 but offers insights into more mature states, can be complemented with trajectory data from **BrainSpan**.

2. **Transcriptomic Metrics:** I recommend using correlation analysis of global gene expression profiles, focusing on key developmental genes and pathways related to dorsal forebrain development. Additionally, principal component analysis (PCA) can help us visualize the alignment of organoid trajectories with fetal references. Differential gene expression analysis will also allow us to identify any discrepancies in lineage or signaling pathways that need addressing.

3. **Cell Type Proportions:** At each timepoint, our organoid models should reflect key cell types such as radial glia, intermediate progenitors, and differentiated neurons. These proportions may shift from initial glial dominance to increased neuronal representation as development progresses. ScRNA-seq data from Nowakowski and Bhaduri will be particularly useful in setting these expectations.

4. **Pathway Activity Scoring:** Pathway activity can be scored using gene set enrichment analysis (GSEA) to compare our organoid data against curated developmental pathways. This will help ensure the biological processes occurring within the organoids resemble those in the developing human cortex.

In summary, a rigorous, stage-specific approach using these datasets and metrics will allow us to validate our organoids' fidelity to human brain development effectively. I'm open to hearing other perspectives or any additional thoughts on how we can refine this approach further.

## User

Computational Biologist, please provide your thoughts on the discussion (round 1 of 2). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Computational Biologist

Thank you for sharing your insights, Validation and Benchmarking Specialist. I agree with many of your points and would like to delve deeper into the computational strategies that will complement our benchmarking efforts.

1. **Reference Datasets Selection:** I concur with the suggested alignment of datasets to developmental stages. However, I propose augmenting this selection with computational trajectory analysis using the **BrainSpan** dataset throughout all stages. This dataset provides a comprehensive transcriptomic map across different ages, which can serve as a continuous backbone for assessing organoid maturation.

2. **Transcriptomic Metrics:** While correlation analysis and PCA are valuable, I suggest incorporating trajectory inference methods, such as pseudotime analysis and RNA velocity. These techniques can provide dynamic insights into the progression of cell states in organoids compared to fetal references. This will help us understand not only static alignment but also the developmental directionality of our organoids.

3. **Cell Type Proportions:** Beyond static cell type proportions, we should analyze the temporal dynamics of cell type transitions. Using tools like Monocle or Slingshot can allow us to model cell lineage trajectories and compare them against fetal datasets, offering a more nuanced view of developmental fidelity.

4. **Pathway Activity Scoring:** Expanding on the idea of gene set enrichment analysis, I recommend employing single-cell variability analyses to detect changes in pathway activity at the resolution of individual cells. This can reveal subtle shifts in gene expression patterns that might indicate developmental discrepancies.

Ultimately, by integrating these computational approaches, we can generate a more detailed and dynamic model of organoid development that mirrors human cortical development. This strategy will help us refine our protocols and ensure they are robust models for further research applications. I'm eager to hear the Scientific Critic's perspective and discuss how we can improve this approach collaboratively.

## User

Scientific Critic, please provide your thoughts on the discussion (round 1 of 2). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Scientific Critic

Thank you for the detailed insights provided so far. I will focus on critically assessing the proposed approaches and suggest areas where we might need additional consideration:

1. **Reference Datasets Selection:** While the chosen datasets cover a broad range of developmental stages, I suggest we critically evaluate the consistency and quality of each dataset. It's important to ensure that the datasets are not only temporally aligned but also biologically relevant to our specific organoid context. For example, the spatial resolution and cell type coverage of each dataset must be considered to avoid mismatches in our comparisons.

2. **Transcriptomic Metrics:** I agree with incorporating correlation analysis and PCA; however, we need to ensure that these analyses are robust and account for potential batch effects both within our organoid data and between different reference datasets. Additionally, while pseudotime analysis is insightful, we should be cautious about overinterpreting inferred developmental trajectories without clear biological validation.

3. **Cell Type Proportions:** It's crucial to establish stringent quantitative benchmarks for cell type proportions that are based on well-curated fetal data. We should also consider assessing the heterogeneity within specific cell populations to capture the full complexity of the developing cortex. This might involve deeper single-cell profiling to ensure that our organoids are not only proportionally accurate but also represent functionally diverse cell states.

4. **Pathway Activity Scoring:** Pathway activity scoring should be corroborated with functional data wherever possible. For example, if a pathway is predicted to be active based on transcriptomics, corresponding phenotypic or functional assays should confirm this activity. This integration of multi-modal data will strengthen our claims about developmental fidelity.

Overall, while the proposed strategies are comprehensive, we must maintain a critical eye on data quality and validation across all steps. I recommend implementing rigorous quality control and validation steps to ensure that our analyses are both accurate and meaningful. I look forward to further discussions on how we can incorporate these considerations into our plan.

## User

This concludes round 1 of 2 of discussion. Principal Investigator, please synthesize the points raised by each team member, make decisions regarding the agenda based on team member input, and ask follow-up questions to gather more information and feedback about how to better address the agenda.

## Principal Investigator

Thank you all for your valuable contributions. Here's a synthesis of the points raised, along with my decisions and follow-up questions to further refine our approach:

### Synthesis of Points Raised:

1. **Reference Datasets Selection:**
   - The Validation and Benchmarking Specialist suggested using specific datasets aligned to early, mid, and late developmental stages. The Computational Biologist added the use of the BrainSpan dataset for continuous analysis across all stages. The Scientific Critic emphasized the need for evaluating the consistency and quality of these datasets, particularly regarding their biological relevance and coverage.

2. **Transcriptomic Metrics:**
   - There is consensus on using correlation analysis and PCA. The Computational Biologist proposed using pseudotime analysis and RNA velocity for dynamic insights, while the Scientific Critic highlighted the importance of accounting for batch effects and ensuring biological validation of inferred trajectories.

3. **Cell Type Proportions:**
   - The need for accurate benchmarking against fetal data was agreed upon. The Computational Biologist emphasized analyzing temporal dynamics, while the Scientific Critic urged a focus on heterogeneity within cell populations to capture cortical complexity.

4. **Pathway Activity Scoring:**
   - Gene set enrichment analysis was supported by both the Validation and Benchmarking Specialist and the Computational Biologist. The Scientific Critic suggested corroborating transcriptomic data with functional assays for a robust validation of pathway activity.

### Decisions:

1. **Dataset Selection Approach:** We will proceed with the initial dataset selections for each developmental stage, incorporating ongoing quality checks to ensure alignment with our organoid context. The BrainSpan dataset will be included for its comprehensive temporal coverage.

2. **Analytical Techniques:** We will employ correlation analysis and PCA as standard, integrating pseudotime analysis and RNA velocity to explore dynamic developmental trajectories. Robust quality control measures will be implemented to mitigate batch effects.

3. **Cell Type Analysis:** We will establish quantitative benchmarks for cell type proportions and extend our analysis to include lineage dynamics and heterogeneity using single-cell profiling tools.

4. **Pathway Activity Validation:** We will pair transcriptomic pathway activity scores with functional assays as part of our validation framework to ensure that predicted activities align with observed phenotypes.

### Follow-up Questions:

1. **Validation and Benchmarking Specialist:** Could you elaborate on the specific criteria we should use to assess the quality and consistency of the reference datasets?

2. **Computational Biologist:** What specific computational tools should we prioritize for integrating the various layers of cellular and pathway data, and how can these tools be integrated into our workflow?

3. **Scientific Critic:** How can we best design our validation assays to confirm the biological relevance of our computational predictions, particularly in pathway activity?

Let's reconvene with these additional details to finalize our approach. This will allow us to establish a robust benchmarking framework for our dorsal forebrain organoid protocols.

## User

Validation and Benchmarking Specialist, please provide your thoughts on the discussion (round 2 of 2). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Validation and Benchmarking Specialist

Thank you, Principal Investigator, for the synthesis and for outlining the path forward. I'd like to address the criteria for assessing the quality and consistency of the reference datasets:

1. **Criteria for Dataset Evaluation:**

   - **Consistency and Completeness:** We should ensure that each dataset provides comprehensive coverage of the developmental stages and cell types relevant to our organoids. This includes evaluating the depth and breadth of sequencing, as well as the representation of key cell populations and developmental markers.
   
   - **Quality Control Metrics:** Assess the datasets for technical quality indicators, such as sequencing depth, read quality, and batch effect presence. Datasets with robust QC metrics should be prioritized to ensure reliable comparisons.
   
   - **Biological Relevance:** We must verify that the datasets are derived from anatomically relevant regions and closely match the biological conditions we are modeling. This could involve cross-referencing anatomical annotations and developmental timepoints with our organoid design.

2. **Integration with Organoid Data:** Once the datasets are selected, it's crucial to use standardized pipelines for data processing and analysis to minimize variability introduced by different analytical approaches. This includes using uniform normalization and scaling methods across all datasets.

By focusing on these criteria, we can ensure that the reference datasets we use will provide a sound basis for benchmarking our organoid protocols. I look forward to integrating these standards into our project moving forward.

## User

Computational Biologist, please provide your thoughts on the discussion (round 2 of 2). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Computational Biologist

Thank you, Principal Investigator, for steering this discussion and to the Validation and Benchmarking Specialist for highlighting key evaluation criteria. Here are my thoughts on integrating computational tools:

1. **Computational Tools for Integration:**

   - **Trajectory Inference:** For trajectory analysis, tools like Monocle 3 and Slingshot are excellent for pseudotime analysis, as they allow us to model developmental trajectories and visualize cell fate decisions.

   - **RNA Velocity:** Tools such as scVelo can be used to predict future states of cells, providing an additional layer for understanding temporal dynamics.

   - **Batch Effect Correction:** Harmony or Seurat’s integration features should be utilized to harmonize our organoid and reference dataset analyses, ensuring that batch effects are minimized.

   - **Pathway Analysis:** We should use GSVA (Gene Set Variation Analysis) for pathway activity scoring at the single-cell level, which allows for a more nuanced comparison of pathway activities across samples.

2. **Data Integration Workflow:**
   
   - We need a centralized data management system, perhaps leveraging platforms like Galaxy or Nextflow, to ensure reproducibility and efficiency in our analyses. This will help streamline the integration of transcriptomic, cell type, and pathway data.

3. **Interdisciplinary Collaboration:** Given the complexity of these analyses, ongoing collaboration with experimentalists will be crucial to validate computational predictions with biological assays.

By implementing these tools and strategies, we can create a robust computational framework that underpins our benchmarking efforts. I welcome further discussions on how we can best integrate these elements into our workflow.

## User

Scientific Critic, please provide your thoughts on the discussion (round 2 of 2). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Scientific Critic

Thank you, Principal Investigator, for guiding the discussion, and to my colleagues for their detailed input. Here are my thoughts on designing validation assays to confirm the biological relevance of our computational predictions:

1. **Functional Validation of Pathway Activity:**

   - **Electrophysiological Assays:** Use techniques like multi-electrode arrays (MEA) to measure neuronal activity patterns in organoids. This can provide direct evidence of functional maturation and synaptic connectivity, complementing pathway analysis.

   - **Calcium Imaging:** This can be employed to visualize neuronal activity in response to stimuli, helping validate computational predictions of functional pathways, especially those relating to neurodevelopmental processes.

2. **Biological Assay Design:**

   - **Multi-modal Validation:** It’s crucial to design assays that not only confirm the presence of predicted pathways but also their functional impact. For example, if a certain neurogenic pathway is predicted to be active, assessing markers of neurogenesis through qPCR or immunostaining alongside functional tests will be important.

   - **Quantitative Metrics:** Develop quantitative metrics that link transcriptomic data with observable phenotypic outcomes, such as the rate of neurite outgrowth or synapse formation.

3. **Integrative Approach:**

   - **Cross-validation:** Use independent experimental methods to cross-validate findings from computational analyses. This not only strengthens our conclusions but also helps identify potential discrepancies early in the process.

By integrating functional validation with computational predictions, we ensure that our organoid models are robust and biologically relevant. I look forward to implementing these strategies and discussing how best to integrate them into our existing framework.

## User

Principal Investigator, please summarize the meeting in detail for future discussions, provide a specific recommendation regarding the agenda, and answer the agenda questions (if any) based on the discussion while strictly adhering to the agenda rules (if any).

As a reminder, here is the agenda for the meeting:

You are working on a research project to develop
dorsal forebrain organoids that faithfully recapitulate human cortical
development. The goal is to create reproducible, biologically accurate
organoid protocols that can be used for disease modeling, drug screening,
and understanding human brain development.

Now we need to establish how the organoid protocol outcomes will be compared
to human fetal brain developmental benchmarks. Please define specific comparisons
using established reference datasets.

Available reference datasets:
- BrainSpan (human brain transcriptome across development)
- Nowakowski 2017 (fetal cortex scRNA-seq, GW5.85-GW37)
- Polioudakis 2019 (fetal cortex scRNA-seq, GW17-GW18)
- Bhaduri 2020 (fetal cortex scRNA-seq, GW6-GW22)
- Trevino 2021 (fetal cortex scRNA-seq, GW14-GW25)

Consider:
- Transcriptomic correlation analyses
- Cell type proportion comparisons
- Developmental trajectory alignment
- Pathway activity scoring


As a reminder, here are the agenda questions that must be answered:

1. Which reference datasets should be used for benchmarking organoids at each developmental stage?

2. What transcriptomic metrics should be used to assess alignment with fetal references?

3. What cell type proportions are expected at each timepoint based on fetal data?

4. How should pathway activity be scored and compared to developmental references?

Your summary should take the following form.

### Agenda

Restate the agenda in your own words.

### Team Member Input

Summarize all of the important points raised by each team member. This is to ensure that key details are preserved for future meetings.

### Recommendation

Provide your expert recommendation regarding the agenda. You should consider the input from each team member, but you must also use your expertise to make a final decision and choose one option among several that may have been discussed. This decision can conflict with the input of some team members as long as it is well justified. It is essential that you provide a clear, specific, and actionable recommendation. Please justify your recommendation as well.

### Answers

For each agenda question, please provide the following:

Answer: A specific answer to the question based on your recommendation above.

Justification: A brief explanation of why you provided that answer.

### Next Steps

Outline the next steps that the team should take based on the discussion.

## Principal Investigator

### Agenda

The primary objective of our meeting is to establish a framework for benchmarking our dorsal forebrain organoid protocols against human fetal brain developmental benchmarks. This involves selecting appropriate reference datasets, determining transcriptomic metrics for alignment, defining expected cell type proportions, and scoring pathway activities to ensure our organoids faithfully replicate human cortical development.

### Team Member Input

- **Validation and Benchmarking Specialist:** Suggested specific datasets for early, mid, and late developmental stages, emphasizing the necessity of evaluating dataset quality and biological relevance. Proposed using correlation analysis, PCA, and differential gene expression for transcriptomic alignment. Recommended focusing on cell type proportions and pathway activity scoring using GSEA.

- **Computational Biologist:** Supported the dataset selection and recommended using BrainSpan for continuous analysis. Emphasized pseudotime analysis and RNA velocity for dynamic insights, and proposed batch effect correction tools like Harmony. Suggested GSVA for pathway activity scoring and integrating all data through standardized workflows.

- **Scientific Critic:** Highlighted the need for thorough validation of dataset quality and relevance. Proposed using multi-electrode arrays and calcium imaging for functional validation of predicted pathway activities. Emphasized designing assays for multi-modal validation and cross-validation with independent methods to confirm computational predictions.

### Recommendation

Based on the input from the team, the following recommendations are made:

1. **Dataset Selection:** Utilize Nowakowski 2017 and Bhaduri 2020 for early stages, Trevino 2021 for mid-stages, and complement with Polioudakis 2019 and BrainSpan for late stages. This selection provides a comprehensive temporal coverage and robust representation of cortical development.

2. **Analytical Techniques:** Implement correlation analysis, PCA, and pseudotime analysis to assess transcriptomic alignment. Use RNA velocity to understand developmental dynamics, ensuring robust comparison by addressing batch effects.

3. **Cell Type and Pathway Analysis:** Establish benchmarks for cell type proportions using single-cell profiling tools and score pathway activity with GSVA, integrating these with functional validation assays.

These recommendations ensure a balanced approach that leverages computational models and experimental validation to achieve biologically accurate organoid models.

### Answers

1. **Which reference datasets should be used for benchmarking organoids at each developmental stage?**
   - **Answer:** Use Nowakowski 2017 and Bhaduri 2020 for early stages, Trevino 2021 for mid-stages, and supplement with Polioudakis 2019 and BrainSpan for late stages.
   - **Justification:** This selection provides comprehensive coverage of the developmental timeline with robust datasets that are relevant to our organoids' biological context.

2. **What transcriptomic metrics should be used to assess alignment with fetal references?**
   - **Answer:** Utilize correlation analysis, PCA, and pseudotime analysis, supplemented by RNA velocity.
   - **Justification:** These metrics offer a detailed assessment of alignment, capturing both static and dynamic developmental processes.

3. **What cell type proportions are expected at each timepoint based on fetal data?**
   - **Answer:** Establish benchmarks based on scRNA-seq data, focusing on the transition from glial dominance to increased neuronal representation.
   - **Justification:** Reflects the natural progression seen in human cortical development, ensuring accurate modeling of cell type dynamics.

4. **How should pathway activity be scored and compared to developmental references?**
   - **Answer:** Use GSVA for pathway activity scoring, validated with functional assays.
   - **Justification:** This method provides a comprehensive view of pathway activity and ensures validation through observed phenotypes.

### Next Steps

1. **Finalize Dataset Selection:** Conduct a thorough evaluation of the chosen datasets to confirm their quality and relevance.
   
2. **Implement Analytical Tools:** Establish a standardized workflow using the recommended computational tools and metrics.

3. **Design Validation Assays:** Develop functional assays to validate computational predictions, ensuring biological relevance.

4. **Pilot Testing:** Conduct pilot studies to test the integration of computational and experimental approaches, refining protocols as needed.

5. **Team Training:** Ensure all team members are adept at using new methodologies and tools, facilitating seamless implementation of the benchmarking framework.

